Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.15 USD | -2.54% | 0.00% | -35.39% |
03-14 | Transcript : Protalix BioTherapeutics, Inc., 2023 Earnings Call, Mar 14, 2024 | |
03-14 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 74.06M 101M | Sales 2025 * | 127M 174M | Capitalization | 84.01M 115M |
---|---|---|---|---|---|
Net income 2024 * | 17M 23.24M | Net income 2025 * | 70M 95.68M | EV / Sales 2024 * | 1.13 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.66 x |
P/E ratio 2024 * |
5.48
x | P/E ratio 2025 * |
1.42
x | Employees | 208 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.23% |
Latest transcript on Protalix BioTherapeutics, Inc.
1 day | -2.54% | ||
Current month | -8.73% | ||
1 month | -8.00% | ||
3 months | -22.30% | ||
6 months | -19.58% | ||
Current year | -35.39% |
Managers | Title | Age | Since |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 19-06-29 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 19-07-21 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 20-07-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 19-11-30 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 19-11-30 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 14-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +2.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.15 | -2.54% | 958,735 |
24-04-25 | 1.18 | -2.48% | 192,155 |
24-04-24 | 1.21 | +0.83% | 228,353 |
24-04-23 | 1.2 | +1.69% | 272,095 |
24-04-22 | 1.18 | +2.61% | 225,065 |
Delayed Quote Nyse, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.39% | 84.01M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- PLX Stock